PD-1 阻断在前列腺癌中（反复）效果不佳。

Cancer Discov. 2023 May 4;13(5):1032-1033. doi: 10.1158/2159-8290.CD-NB2023-0017.

Late-stage trials evaluating the PD-1 inhibitor pembrolizumab in men with prostate cancer have all ended in failure, leading clinicians to conclude that new treatment strategies are needed to help make checkpoint blockade more effective in the immune-suppressed environment of most prostate tumors.

评估 PD-1 抑制剂 pembrolizumab 在前列腺癌男性患者中的晚期试验均以失败告终，这导致临床医生得出结论，需要新的治疗策略来帮助使检查点阻断在大多数前列腺肿瘤的免疫抑制环境中更有效。